Announcements Trials

Browse Landscape

Phase

Phase NA 23 Phase EARLY_PHASE1 1 Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Cancer Recurrence 1

Interventions

Cyclophosphamide 624 pembrolizumab 500 Paclitaxel 456 Gemcitabine 438 Carboplatin 435 Cisplatin 418 Radiotherapy 380 fludarabine 365 Nivolumab 340 Docetaxel 277 Bevacizumab 276 Irinotecan 257 Magnetic Resonance Spectroscopy 242 Fluorouracil 228 Dexamethasone 225 Specimen Handling 221 Capecitabine 218 Rituximab 205 Cytarabine 201 Oxaliplatin 200 Ipilimumab 199 Temozolomide 197 Biopsy 196 fludarabine phosphate 194 Etoposide 181 Lenalidomide 176 Doxorubicin 175 Leucovorin 173 Cetuximab 171 Injections 170

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Acceptance and Commitment Therapy × Clear all

NCT01354041 2014-01-27

WiLLoW

University of California, San Francisco

Phase 1 Completed

Cancer Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡